Clinical Trials Browser

Phase 1/2 × Leukemia, Lymphoid × Alemtuzumab × Clear all

NCT00935792 2017-09-26

Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 1/2 Completed

28 enrolled 13 charts

Other hematologic neoplasm

Leukemia, Lymphoid, Hematologic Neoplasms